glp-1 drugs trulicity Lawsuit - July 2026 Update Two patients taking the GLP-1

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl peptidase-4 inhibitors, according to findings scheduled for presentation at ASCO Annual Meeting

Probiotics Given the gut-thyroid connection discussed earlier, probiotic supplementation makes physiological sense for Hashimoto's patients on GLP-1 therapy

Bolli et al demonstrated significant weight loss with lixisenatide after 24 weeks as compared to placebo (1.1 to 1.0 kg least squares mean difference

The 78-week PIONEER-3 study compared 1864 adults with diagnosed type-2 diabetes who received either metformin (with or without sulfonylurea), oral semaglutide in three different dosages, or sitagliptin (100 mg/d)